Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on May 18, 2022. The filing primarily addresses the progression of a proposed acquisition of Emerald Health Therapeutics, Inc. ("EHT") and a concurrent change in the company's board of directors.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Support Agreements: On May 18, 2022, Skye and EHT entered into support agreements with Emerald Health Sciences, Inc. ("EHS"). EHS agreed to vote its EHT shares in favor of the Arrangement Agreement (the acquisition) and against alternative proposals. Similarly, EHS agreed to vote its Skye Common Stock in favor of adopting the Arrangement Agreement.
- Board Resignation: Jim Heppell resigned from Skye's board of directors and all associated committees (audit, compensation, and nominating/corporate governance) effective May 18, 2022. The resignation is attributed to other commitments and is not the result of any disagreement with the company.
Guidance, Outlook, and Risks
Outlook and Next Steps: Skye intends to file a proxy statement on Schedule 14A containing detailed information regarding the proposed transaction. Shareholders are urged to review the management information circular and proxy statement before voting. These documents will be available via SEDAR and EDGAR.
Risks and Contingencies: The support agreements entered into with EHS are contingent upon the Arrangement Agreement remaining in effect; they will terminate if the Arrangement Agreement is terminated. The filing explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy securities.
Investor Verification Checklist
- Verify the terms of the Arrangement Agreement filed on May 11, 2022, to understand the acquisition structure.
- Review the upcoming Schedule 14A proxy statement for detailed financial and operational data regarding the proposed merger.
- Confirm the voting instructions for Skye and EHT shareholders regarding the support agreements with EHS.
- Monitor the status of the Arrangement Agreement, as the support agreements are contingent on its continuation.